Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in advanced biliary cancers
NCT02520141Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in cholangiocarcinoma (CCA), gallbladder cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT02520141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520141.